Omega Therapeutics, Inc. OMGA
At closeFeb 24, 2025, 4:00 PM EST
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 7.90M
- Revenue (ttm)
- 6.31M
- EPS (ttm)
- -1.33
- Shares out
- 55.37M
- Forward P/E
- -0.89
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 4.28M
- Avg volume
- 26.37M
- Open
- 0.166
- Previous close
- 0.1426
- Day's range
- 0.1426 – 0.166
- 52-week range
- 0.10 – 2.63
- Beta
- 1.84
- Price target
- 9.50 (+6562.0%)
- Earnings date
- Aug 6, 2024
Key statistics
- Enterprise value
- 126.79M
- PEG ratio
- 0.00
- Price / sales
- 7.11
- Price / book
- 0.77
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 181.20%
- Free cash flow
- -41.81M
- Total cash
- 45.85M
- Total debt
- 126.95M
- Return on equity
- -129.15%
- Short % of float
- 33.20%
- 50-day average
- 1.00
- 200-day average
- 1.82
Analyst view
- Target (low)
- 4.00
- Target (mean)
- 9.50
- Target (high)
- 12.00
- Strong buy2
- Buy4
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate -0.26333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.29 | -0.30 | -0.01 | -3.45% |
| Aug 6, 2024 | Jun 1, 2024 | -0.36 | — | — | — |
| Aug 6, 2024 | Jun 1, 2024 | -0.36 | -0.30 | +0.06 | +16.67% |
| May 6, 2024 | Mar 1, 2024 | -0.38 | — | — | — |
| May 6, 2024 | Mar 1, 2024 | -0.38 | -0.36 | +0.02 | +5.26% |
| Mar 28, 2024 | Dec 1, 2023 | -0.46 | -0.37 | +0.09 | +19.57% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | Piper Sandler | main | Overweight | Overweight |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 7, 2024 | Wedbush | reit | Outperform | Outperform |
| Aug 7, 2024 | Chardan Capital | main | Buy | Buy |
| Jun 18, 2024 | Raymond James | init | — | Outperform |
| May 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Omega Therapeutics, Inc.
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- omegatherapeutics.com
News
Omega Pacific Commences Drill Program at Williams Property 
Omega Pacific Williams Property Exploration Program Update 
Omega Pacific Outlines 2026 Exploration Program at the Williams Property 
Omega Pacific Closes First Tranche of Non-Brokered Private Placement 
Omega Pacific Clarifies Size of Previously Announced Private Placement 
Omega Pacific Announces Non-Brokered Private Placement 
Omega Pacific Acquires 100% of Williams Property 
Omega Pacific Closes Non-Brokered Private Placement 
Omega Pacific Closes First Tranche of Offering 
Omega Pacific Announces Private Placement
Your note
Sign in to keep a note on OMGA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FLAGSHIP PIONEERING, INC. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 26, 2023 | 0 |
| YOUNG RICHARD A | Director | Sale | Jun 1, 2023 | 739,118 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Flagship Pioneering Inc. | 52.79% | 29,225,579 | 23.70M | Sep 29, 2024 |
| FMR, LLC | 10.95% | 6,062,104 | 4.92M | Sep 29, 2024 |
| Harbourvest Partners, LLC | 6.34% | 3,512,110 | 2.85M | Sep 29, 2024 |
| State Of Wisconsin Investment Board | 3.35% | 1,857,265 | 1.51M | Sep 29, 2024 |
| Siren, L.L.C. | 2.39% | 1,323,530 | 1.07M | Sep 29, 2024 |
| Vanguard Group Inc | 2.01% | 1,114,731 | 904.05K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 3.63% | 2,012,406 | 1.63M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.41% | 779,100 | 631.85K | Sep 29, 2024 |
| Fidelity Growth Company K6 Fund | 1.36% | 752,855 | 610.57K | Oct 30, 2024 |
| Fidelity Series Growth Company Fund | 0.79% | 434,979 | 352.77K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.56% | 309,866 | 251.30K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.22% | 123,532 | 100.18K | Oct 30, 2024 |